Phase 2 clinical trial of EC-104 for DME meets primary endpoint
A phase 2 clinical trial investigating EC-104, a fluocinolone acetonide extended-release intravitreal implant for the treatment of diabetic macular edema, met its primary endpoint, according to a press release from Eclipse Life Sciences.
As Healio previously reported, the BETTIS-1 trial compared two doses of fluocinolone acetonide, 0.14 mg and 0.092 mg, with Ozurdex (dexamethasone intravitreal implant, AbbVie) in patients with DME who had a previous suboptimal clinical response to intravitreal anti-VEGF therapy.
The primary endpoint, safety of both doses compared with dexamethasone implant, was